Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Clinical relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain‐free response at 2 h · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Headache relief at 2 h · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Headache relief at 1 h · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Sustained pain‐free during the 24 h post dose · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Sustained headache relief during the 24 h post dose · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
At least one AE · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Serious AE* · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Mycological cure · patients with tinea cruris and tinea corporis
Azoles showed no clear difference in mycological cure Negative KOH microscopy and culture. Treatment… compared with moderate‐potent corticosteroid/azole combinations (low certainty).
1 finding from 1 review
Clinical cure · patients with tinea cruris and tinea corporis
It is very uncertain whether azoles changes clinical cure (immediately at end of treatment) Resolution of… compared with moderate‐potent corticosteroid/azole combinations (very low certainty).
1 finding from 1 review
Adverse effects Reported by investigators 'and' or 'or' participants · patients with tinea cruris and tinea corporis
It is very uncertain whether azoles changes adverse effects Reported by investigators 'and' or 'or' participants compared with moderate‐potent corticosteroid/azole combinations (very low certainty).
1 finding from 1 review
Relapse or recurrence Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review
Cure · patients with tinea cruris and tinea corporis
1 finding from 1 review
Duration of treatment until clinical cure Not assessed · patients with tinea cruris and tinea corporis
1 finding from 1 review